Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Artigo
|
![]() |
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trialWilliams, Bryan, Prof ; MacDonald, Thomas M, Prof ; Morant, Steve, PhD ; Webb, David J, Prof ; Sever, Peter, Prof ; McInnes, Gordon, Prof ; Ford, Ian, Prof ; Cruickshank, J Kennedy, Prof ; Caulfield, Mark J, Prof ; Salsbury, Jackie, Prof ; Mackenzie, Isla, FRCP ; Padmanabhan, Sandosh, FRCP ; Brown, Morris J, ProfThe Lancet (British edition), 2015-11, Vol.386 (10008), p.2059-2068 [Periódico revisado por pares]England: Elsevier LtdTexto completo disponível |
2 |
Material Type: Artigo
|
![]() |
Blocking aldosterone or its receptor-what is the difference?Agarwal, RajivThe Lancet (British edition), 2024-01, Vol.403 (10424), p.330-332 [Periódico revisado por pares]England: Elsevier LimitedTexto completo disponível |
3 |
Material Type: Artigo
|
![]() |
Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational studyDouma, Stella, MD ; Petidis, Konstantinos, MD ; Doumas, Michael, Dr ; Papaefthimiou, Panagiota, MD ; Triantafyllou, Areti, MD ; Kartali, Niki, MD ; Papadopoulos, Nikolaos, MD ; Vogiatzis, Konstantinos, PhD ; Zamboulis, Chrysanthos, ProfThe Lancet (British edition), 2008-06, Vol.371 (9628), p.1921-1926 [Periódico revisado por pares]England: Elsevier LtdTexto completo disponível |
4 |
Material Type: Artigo
|
![]() |
Spironolactone plus patiromer: proceed with cautionGanesan, Calyani ; Pao, Alan CThe Lancet (British edition), 2019-10, Vol.394 (10208), p.1486-1488 [Periódico revisado por pares]England: Elsevier LtdTexto completo disponível |
5 |
Material Type: Artigo
|
![]() |
Spironolactone for resistant hypertension—hard to resist?Sternlicht, Hillel ; Bakris, George LThe Lancet (British edition), 2015-11, Vol.386 (10008), p.2032-2034 [Periódico revisado por pares]England: Elsevier LtdTexto completo disponível |
6 |
Material Type: Artigo
|
![]() |
PATHWAY-2: spironolactone for resistant hypertension – Authors' replyWilliams, Bryan ; MacDonald, Tom M ; Morant, Steven V ; Brown, Morris JThe Lancet (British edition), 2016-04, Vol.387 (10026), p.1373-1374 [Periódico revisado por pares]England: Elsevier LtdTexto completo disponível |
7 |
Material Type: Artigo
|
![]() |
PATHWAY-2: spironolactone for resistant hypertensionGkaliagkousi, Eugenia ; Gavriilaki, Eleni ; Triantafyllou, Areti ; Douma, StellaThe Lancet (British edition), 2016-04, Vol.387 (10026), p.1372-1372 [Periódico revisado por pares]England: Elsevier LtdTexto completo disponível |
8 |
Material Type: Artigo
|
![]() |
PATHWAY-2: spironolactone for resistant hypertensionDale, Aaron ; Hartley, Philip ; Goldacre, BenThe Lancet (British edition), 2016-04, Vol.387 (10026), p.1372-1373 [Periódico revisado por pares]England: Elsevier LtdTexto completo disponível |
9 |
Material Type: Artigo
|
![]() |
PATHWAY-2: spironolactone for resistant hypertensionBoutari, Chrysoula ; Stavropoulos, Konstantinos ; Imprialos, Konstantinos ; Doumas, Micheal ; Karagiannis, AsteriosThe Lancet (British edition), 2016-04, Vol.387 (10026), p.1371-1372 [Periódico revisado por pares]England: Elsevier LtdTexto completo disponível |
10 |
Material Type: Artigo
|
![]() |
Spironolactone and congestive heart-failureGeorges, Benoît ; Beguin, Claire ; Jadoul, MichelThe Lancet (British edition), 2000-04, Vol.355 (9212), p.1369-1370 [Periódico revisado por pares]England: Elsevier LtdTexto completo disponível |